June 16, 2015
New research into plaque types and deposition patterns in Alzheimer's disease (AD) and dementia has been presented at annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI; Baltimore, MD, USA) during June 6–10, 2015.
The researchers used the diagnostic imaging agent florbetaben F18 (FBB) in Positron Emission Tomography (PET) to provide detailed information about the quantification and distribution of beta-amyloid plaques in the brain. One analysis evaluated data to determine the ability of FBB PET scans to detect beta-amyloid deposits that were morphologically distinct. Another study assessed the influence of cerebellar plaques on FBB Standardized Uptake Value Ratios (SUVR), using cerebellar gray matter as reference.